Vtama (tapinarof) is a once-daily topical cream that treats plaque psoriasis by activating a specific receptor in skin cells called the aryl hydrocarbon receptor, or AhR. Unlike topical steroids, which suppress the immune system broadly, Vtama works through a more targeted pathway that reduces inflammation, dials down overactive immune signaling, and helps restore the skin’s protective barrier. It’s the first in its drug class, and it works in a fundamentally different way than most topical psoriasis treatments.
The AhR Pathway: Vtama’s Core Mechanism
Every cell in your skin contains aryl hydrocarbon receptors. These receptors act like switches that regulate inflammation and skin health. When you apply Vtama, the active ingredient (tapinarof) binds to and activates these receptors across multiple cell types in the skin, setting off a cascade of effects.
The most important effect is reducing inflammatory signaling. In psoriasis, immune cells in the skin pump out inflammatory proteins (cytokines) that drive the red, thick, scaly plaques. Vtama’s activation of AhR tamps down the production of these cytokines, including those made by a type of immune cell called CD4+ T cells, which are central to the psoriasis disease process. Animal studies confirmed this mechanism definitively: in mice with functioning AhR, tapinarof reduced redness, skin thickening, and tissue inflammation. In mice genetically lacking AhR, the drug had no effect at all. The entire therapeutic benefit depends on this single receptor.
Repairing the Skin Barrier
Psoriasis doesn’t just cause visible plaques. It also weakens the skin’s barrier, the outermost layer that keeps moisture in and irritants out. People with psoriasis have lower levels of key structural proteins that hold this barrier together.
Vtama directly addresses this. Through AhR activation, it boosts the production of three barrier proteins: filaggrin, loricrin, and involucrin. These proteins are essential building blocks that give the outer layer of skin its structure and resilience. Vtama also increases ceramide levels, the fatty lipids that fill the gaps between skin cells like mortar between bricks. Together, these changes help normalize the skin barrier, which contributes to symptom improvement beyond just reducing redness and scaling.
The Remittive Effect
One of Vtama’s most distinctive features is what happens after you stop using it. In a long-term clinical trial (PSOARING 3), patients who achieved completely clear skin while on Vtama maintained that clearance for roughly 4 months on average after discontinuing treatment. This is unusual for a topical psoriasis therapy. Most topical treatments, especially steroids, see symptoms return quickly once you stop applying them.
About 41% of patients in the long-term trial achieved complete clearance at some point during treatment. For those patients, the average off-therapy remission lasted approximately 4 months. Researchers have described this as a “remittive effect,” suggesting the drug creates a more lasting change in the skin rather than simply suppressing symptoms while it’s being applied.
How Vtama Differs From Topical Steroids
Topical corticosteroids have been the backbone of psoriasis treatment for decades, but they come with well-known drawbacks. Long-term use can thin the skin (atrophy), cause visible blood vessels (telangiectasia), and lead to tachyphylaxis, where the medication gradually loses effectiveness and you need stronger formulations to get the same results.
Vtama carries none of these risks. It’s a non-steroidal treatment, so it doesn’t cause skin thinning even with extended use. In clinical trials lasting up to a year, there was no evidence of tachyphylaxis. The drug kept working with intermittent or continuous use without losing potency. This makes it particularly appealing for sensitive skin areas like the face, skin folds, or any location where long-term steroid use would be problematic. In studies where patients used Vtama alongside corticosteroids, no cases of steroid-related skin atrophy or visible blood vessels were observed during follow-up.
How to Apply Vtama
Vtama comes as a 1% cream (10 mg of tapinarof per gram). You apply a thin layer to affected skin once daily. It should go only on psoriasis plaques, not on surrounding unaffected skin. It’s not meant for use in the eyes, mouth, or vaginal area.
There’s no limit on how long you can use it, which is a meaningful practical advantage. With potent topical steroids, dermatologists typically restrict treatment to a few weeks at a time to avoid skin damage. Vtama’s safety profile allows for ongoing or intermittent use as needed.
Common Side Effects
Vtama’s most frequently reported side effect is folliculitis, an inflammation of hair follicles that looks like small red bumps or pimples. Across clinical trials, this occurred in roughly 8 to 12% of patients, though rates as high as 20% were seen in one smaller study. Other common side effects include headache (about 6.5% of patients), upper respiratory symptoms like nasopharyngitis (4.4%), and acne (1.8%). Contact dermatitis occurred in 1 to 3.5% of patients across different trials, and application site irritation was uncommon at under 1%.
Folliculitis is worth knowing about because it can be mistaken for a worsening of psoriasis or a skin infection. It’s generally mild and manageable, but if you notice small, pimple-like bumps around hair follicles in the treated area, that’s the most likely explanation.